n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial

Abstract

Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort.

Trial registration: ClinicalTrials.gov NCT01310270.

Keywords: fatty acids; peripheral artery disease; randomized controlled trials.

Conflict of interest statement

Declaration of conflicting interest

The authors have no conflicts of interest to declare.

Figures

Figure I

OMEGA-PAD trial.

Figure 2

Study protocol.